tiprankstipranks
Advertisement
Advertisement
Protagonist Therapeutics: Emerging Multi-Asset Revenue Streams and Robust Pipeline Drive Buy Rating Ahead of Rusfertide Approval
PremiumRatingsProtagonist Therapeutics: Emerging Multi-Asset Revenue Streams and Robust Pipeline Drive Buy Rating Ahead of Rusfertide Approval
15d ago
Protagonist Therapeutics price target raised to $173 from $116 at Clear Street
Premium
The Fly
Protagonist Therapeutics price target raised to $173 from $116 at Clear Street
15d ago
Protagonist Therapeutics: Diversified Pipeline Progress and Strong Cash Position Drive Buy Rating and Price Target Hike from $130 to $175
Premium
Ratings
Protagonist Therapeutics: Diversified Pipeline Progress and Strong Cash Position Drive Buy Rating and Price Target Hike from $130 to $175
15d ago
Analyst Tara Bancroft Boosts Protagonist Therapeutics Price Target to $155 on Stronger Icotyde Royalty Outlook and Buy Rating
PremiumRatingsAnalyst Tara Bancroft Boosts Protagonist Therapeutics Price Target to $155 on Stronger Icotyde Royalty Outlook and Buy Rating
1M ago
Protagonist Therapeutics price target raised to $165 from $137 at Citizens
Premium
The Fly
Protagonist Therapeutics price target raised to $165 from $137 at Citizens
1M ago
Protagonist Therapeutics price target raised to $151 from $119 at Barclays
Premium
The Fly
Protagonist Therapeutics price target raised to $151 from $119 at Barclays
1M ago
Protagonist Therapeutics price target raised to $110 from $97 at Goldman Sachs
PremiumThe FlyProtagonist Therapeutics price target raised to $110 from $97 at Goldman Sachs
4M ago
Protagonist Therapeutics management to meet virtually with Clear Street
Premium
The Fly
Protagonist Therapeutics management to meet virtually with Clear Street
4M ago
Protagonist Therapeutics participates in a conference call with JPMorgan
Premium
The Fly
Protagonist Therapeutics participates in a conference call with JPMorgan
4M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100